August 2025

Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study

RMD Open 2025;11:e005806 doi: 10.1136/rmdopen-2025-005806

In this nationwide observational study, ixekuzumab was mainly used in patients with axSpA and PsA who had previously failed multiple b/tsDMARDs, including other IL-17 inhibitors. Although prior IL-17 treatment was associated with increased risk of withdrawal in both groups, the relatively high retention rates and improvements in all disease outcomes suggest ixekizumab as a viable option for challenging patients with multiple b/tsDMARD failures.

Keywords:

Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis

Biomedicines 2025;13:2089 Doi: 10.3390/biomedicines13092089

This study by Lee et al. is the first to evaluate the association between adalimumab dosing intervals and uveitis recurrence in patients with AS. Authors investigated whether extending the dosing interval of adalimumab influences the recurrence of uveitis in AS patients with a history of AU who are on adalimumab therapy.

Keywords:

Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)

Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559

In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.

Keywords:

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: A pooled analysis of patients from the Phase 3 KEEPsAKE 1 and 2 studies

RMD Open 2025;11:e005522 Doi:10.1136/rmdopen-2025-005522

Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all the GRAPPA disease domains and related conditions. This post hoc analysis by Coates et al. aimed to assess the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA.

Keywords:

Comparative effectiveness and safety of adalimumab, secukinumab, and upadacitinib in psoriatic arthritis: A prospective cohort study based on PARWCH cohort

J Dermatol 2025 Doi: 10.1111/1346-8138.17906 Epub ahead of print

Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.

Keywords:

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy

RMD Open 2025;11:e005-21 Doi: 10.1136/rmdopen-2025-005521

Most patients vaccinated with RZV while using UPA 15mg QD and background MTX achieved satisfactory humoral and cell-mediated immune responses to recombinant zoster vaccine (RZV) at Weeks 4, 16 and 60. Winthrop et al. evaluated the immunogenicity of RZV through Week 60 in patients with RA who were receiving UPA 15mg QD and background MTX.

Keywords:

July 2025

Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers

J Am Acad Dermatol 2025;93:104–14 doi: 10.1016/j.jaad.2025.03.016

In this nationwide study of Swedish PsO and PsA patients treated with ustekinumab, etanercept, adalimumab, or secukinumab, spanning more than 10 years, the overall risk of MACE was low across treatment groups. There was no meaningful difference in risk of MACE between ustekinumab and the other treatments.

Keywords:

Roflumilast foam, 0.3%, for psoriasis of the scalp and body the ARRECTOR Phase 3 randomized clinical trial

JAMA Dermatol 2025;7:698–706 doi: 10.1001/jamadermatol.2025.1136

Gooderham et al. observed that roflumilast foam, 0.3%, improved signs and symptoms of PsO on the scalp and body, including pruritus, with low rates of AEs in patients ≥12 years of age. Authors assessed efficacy and safety of roflumilast foam, 0.3%, versus vehicle administered QD for 8 weeks in patients with PsO of the scalp and body.

Keywords:

A randomized Phase II study of efmarodocokin alfa, an interleukin-22 agonist, versus vedolizumab in patients with ulcerative colitis

Clinical Gastroenterology and Hepatology 2025;23:1387–1397 doi: 10.1016/j.cgh.2024.11.013

Danese et al. observed that efmarodocokin alfa did not demonstrate efficacy compared to the PBO, and this Phase II study ended early for futility; however, there was evidence of target engagement (skin AEs, regenerating islet derived protein 3-alpha).

Keywords:

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: A post hoc analysis from placebo-controlled Phase 3 studies with secukinumab

Ther Adv Musculoskelet Dis. 2025;17:1–7

Brandt-Jürgens et al. identified a difference between the incidence rates of uveitis in patients with PsA or axSpA when treated with secukinumab compared to placebo. The authors conducted a post hoc analysis of 11 placebo-controlled clinical trials which has observed that uveitis incidences in patients with PsA are consistent with clinical trial data, and patients with axSpA show a lower incidence of uveitis compared to other publications.

Keywords: